Neuren Media and Analyst Coverage, page-792

my DCF model for Daybue alone, without NNZ2591, with Daybue sales in the rest of the world commencing in 2026 with a retail price of $200k USD gives a NPV per share of $A50.33. If I assume success for 2591 for all 4 indications currently being trialed, and sales commencing in the USA only in 2029 and 2030 across all 4, with similar pricing to Daybue in the US of $350k per patient per year,, and with the same milestone payments as Daybue, the NVP of discounted cash flow increases to $A135/share. So 2591 adds $85/share to the value of NEU on top of the base case of Daybue only. That's the difference between 0% chance of success for 2591 and 100% COS. I haven't priced in any middle ground like the brokers probably do. It's either all or nothing.